Inhibikase Therapeutics to Present at the 2023 Planet MicroCap Showcase

Rhea-AI Summary

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) announced its participation in the 2023 Planet MicroCap Showcase on April 26, 2023, at the Horseshoe Hotel & Casino in Las Vegas. Dr. Milton Werner, President & CEO, and Joseph Frattaroli, CFO, will present at 1:00 PM PT. The company is focused on developing therapeutics targeting Parkinson's disease and related disorders, highlighting its lead program, IkT-148009, which inhibits Abelson Tyrosine Kinases (c-Abl). Inhibikase's pipeline also includes therapies for gastrointestinal disorders related to Parkinson's and innovative drug delivery technologies. The event offers an opportunity for investors to gain insights into the company’s strategies and advancements in neurodegeneration treatments.

News Market Reaction

+1.61%

1 alert

+1.61% News Effect

On the day this news was published, IKT gained 1.61%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

BOSTON and ATLANTA, April 21, 2023 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced that Dr. Milton Werner, Ph.D., President & Chief Executive Officer of Inhibikase, and Joseph Frattaroli, Chief Financial Officer of Inhibikase, will deliver a presentation at the 2023 Planet MicroCap Showcase being held on April 25-27, 2023 in Las Vegas, Nevada.

Presentation Details:

Event: Planet MicroCap Showcase 2023
Presentation Date: Wednesday, April 26, 2023
Presentation Time: 1:00pm PT
Location: Horseshoe Hotel & Casino, Track 5 Company Presentations

About Inhibikase (www.inhibikase.com)
Inhibikase Therapeutics, Inc. (Nasdaq: IKT) is a clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and related disorders. Inhibikase's multi-therapeutic pipeline has a primary focus on neurodegeneration and its lead program IkT-148009, an Abelson Tyrosine Kinase (c-Abl) inhibitor, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Ableson Tyrosine Kinases. Its multi-therapeutic pipeline is pursuing Parkinson's-related disorders of the brain and GI tract, orphan indications related to Parkinson's disease such as Multiple System Atrophy, and drug delivery technologies for kinase inhibitors such as IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate that the Company believes will provide a better patient experience with fewer on-dosing side-effects. The Company's RAMP™ medicinal chemistry program has identified a number of follow-on compounds to IkT-148009 to be potentially applied to other cognitive and motor function diseases of the brain. Inhibikase is headquartered in Atlanta, Georgia with an office in Lexington, Massachusetts.

Social Media Disclaimer
Investors and others should note that we announce material financial information to our investors using our investor relations website, press releases, SEC filings and public conference calls and webcasts. The Company intends to also use Twitter, Facebook, LinkedIn and YouTube as a means of disclosing information about the Company, its services and other matters and for complying with its disclosure obligations under Regulation FD.

Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking terminology such as "believes," "expects," "may," "will," "should," "anticipates," "plans," or similar expressions or the negative of these terms and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based on Inhibikase's current expectations and assumptions. Such statements are subject to certain risks and uncertainties, which could cause Inhibikase's actual results to differ materially from those anticipated by the forward-looking statements, including that results in animal studies may not be replicated in humans. Important factors that could cause actual results to differ materially from those in the forward-looking statements include factors that are delineated in our periodic reports on Form 10-K and Form 10-Q that we file with the U.S. Securities and Exchange Commission. Any forward-looking statement in this release speaks only as of the date of this release. Inhibikase undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws.

Contacts:

Company Contact:
Milton H. Werner, PhD
President & CEO
678-392-3419
info@inhibikase.com

Investor Relations:
Alex Lobo
SternIR, Inc.
alex.lobo@sternir.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/inhibikase-therapeutics-to-present-at-the-2023-planet-microcap-showcase-301803705.html

SOURCE Inhibikase Therapeutics, Inc.

FAQ

What is the presentation date for Inhibikase at the 2023 Planet MicroCap Showcase?

Inhibikase will present on April 26, 2023.

What time will Inhibikase present at the Planet MicroCap Showcase?

Inhibikase's presentation is scheduled for 1:00 PM PT.

Where is the 2023 Planet MicroCap Showcase being held?

The event is taking place at the Horseshoe Hotel & Casino in Las Vegas.

What is Inhibikase Therapeutics' ticker symbol?

Inhibikase Therapeutics is listed on Nasdaq under the ticker symbol IKT.

What is the focus of Inhibikase Therapeutics' drug development?

The company focuses on developing therapeutics for Parkinson's disease and related disorders.

Who are the presenters representing Inhibikase at the Planet MicroCap Showcase?

The presenters are Dr. Milton Werner and Joseph Frattaroli.